UCB Stock Surges 13% as Bimzelx Demand Forces a Second Guidance Raise in One Year

UCB Raised Its 2026 Guidance for the Second Time This Year

UCB stock surged on Thursday, October 22, 2026, after the Belgian pharmaceutical company raised its full-year 2026 guidance for the second time this year. The company said strong U.S. demand for its immunology drug Bimzelx, supported by robust patient demand and favorable pricing, drove the upgrade, with older anti-inflammatory drug Cimzia also contributing. Shares rose 13% in European morning trading, erasing their losses for the year to date.

What Happened

UCB now expects 2026 revenue growth in the low-twenties percentage range at constant currency, up sharply from its previous forecast of growth in the low- to mid-teens. The upgrade on profitability was even larger: the company now expects adjusted EBITDA growth in the low- to mid-forties percentage range at constant currency, compared with its earlier guidance of growth in the mid-teens to low-twenties range.

That is not a small tweak. In one update, UCB roughly doubled the growth rate it expects for its core profit measure, and it did so with only a little over two months left in the year — a sign that the momentum behind Bimzelx in the United States is running ahead of what management itself had planned for.

UCB also noted that the new guidance excludes proceeds from the sale of a priority-review voucher, a U.S. Food and Drug Administration incentive. That sale is expected to add a further low- to mid-single-digit percentage-point uplift to both revenue and adjusted EBITDA growth, meaning the reported figures could come in higher still.

Why It's Blowing Up

Guidance raises are common in earnings season. Guidance raises of this size, this late in the year, are not. According to FactSet data cited by Dow Jones, if the morning gain held to the close it would be UCB's biggest one-day percentage gain in more than a year — and the move wiped out the stock's entire year-to-date decline in a single session.

The story resonating with investors is concentration working in UCB's favor. Bimzelx, its blockbuster immunology treatment, is seeing higher patient demand and retention in the U.S. alongside favorable net pricing, while Cimzia continues to grow volumes with improved pricing. When a company's lead drug beats on both volume and price at the same time, analysts tend to revisit their forecasts for several years, not just the current one — which is why ING analysts said the update should lead to significant upgrades to consensus expectations.

The reaction also stood out against a difficult day elsewhere in markets, where technology stocks were under pressure on renewed worries about AI spending. A healthcare name delivering a clean, company-specific upgrade gave investors something concrete to buy while broader sentiment wobbled.

Key Facts

• Guidance raise: 2026 revenue growth now expected in the low-20% range at constant currency, up from low- to mid-teens previously.
• Profit outlook: Adjusted EBITDA growth now expected in the low- to mid-40% range at constant currency, up from mid-teens to low-20s.
• Stock move: Shares up 13% in European morning trading on October 22, erasing year-to-date losses.
• Driver: Strong U.S. performance from Bimzelx — higher patient demand, retention and favorable net pricing — plus continued Cimzia volume growth and improved pricing.
• Extra uplift not in guidance: Sale of an FDA priority-review voucher is expected to add a further low- to mid-single-digit percentage points to revenue and adjusted EBITDA growth.
• Frequency: This is UCB's second guidance increase of 2026.

What's Next

The next question is whether analysts follow through with the forecast upgrades ING predicted, and whether Bimzelx's U.S. momentum holds into 2027 guidance season. Investors will also watch for final terms on the priority-review voucher sale, which sits on top of the raised outlook rather than inside it. For now, UCB has delivered one of the clearest positive surprises of this earnings season: a late-year, double-digit guidance raise powered by a single drug outperforming in the world's largest pharmaceutical market. This post reports what happened and why markets reacted; it is not financial advice.

Sources

• Morningstar / Dow Jones Newswires — UCB Shares Jump After Demand for Immunology Drug Bimzelx Boosts Outlook
• Reuters via TradingView — UCB upgrades 2026 guidance on strong US Bimzelx sales
• The Wall Street Journal — UCB Shares Jump After Demand for Immunology Drug Bimzelx Boosts Outlook
• Newsquawk — Daily European Equity Opening News, 22nd October 2026

FAQ

Why did UCB stock jump 13% on October 22, 2026?

UCB raised its 2026 guidance for the second time this year, citing strong U.S. demand and favorable pricing for its immunology drug Bimzelx, and the shares rose 13% in morning trading, erasing their year-to-date losses.

What is UCB's new 2026 guidance?

UCB now expects revenue growth in the low-20% range and adjusted EBITDA growth in the low- to mid-40% range at constant currency, up from low- to mid-teens revenue growth and mid-teens to low-20s EBITDA growth previously.

What is Bimzelx?

Bimzelx is UCB's blockbuster immunology drug. Its strong U.S. performance — higher patient demand, retention and favorable net pricing — was the main driver management cited for the guidance raise, alongside continued growth from Cimzia.

Does the new guidance include the priority-review voucher sale?

No. UCB said the upgraded guidance excludes proceeds from selling an FDA priority-review voucher, which it expects to add a further low- to mid-single-digit percentage-point uplift to revenue and adjusted EBITDA growth.